Latest filings (excl ownership)
8-K
Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026
11 Apr 24
ARS
2023 FY
Annual report to shareholders
5 Apr 24
DEFA14A
Additional proxy soliciting materials
5 Apr 24
DEF 14A
Definitive proxy
5 Apr 24
10-K
2023 FY
Annual report
22 Feb 24
8-K
Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results
22 Feb 24
8-K
Regulation FD Disclosure
3 Jan 24
8-K
Other Events
9 Nov 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Collegium Reports Third Quarter 2023 Financial Results
7 Nov 23
8-K
Collegium Announces Extension of Nucynta Regulatory Exclusivity through July 2026
24 Aug 23
S-8
Registration of securities for employees
10 Aug 23
8-K
Other Events
7 Aug 23
8-K
Collegium Reports Record 1H’23 Net Revenue of $280.3 Million, Up 35% Year-over-Year
3 Aug 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
19 May 23
10-Q
2023 Q1
Quarterly report
4 May 23
8-K
Collegium Reports First Quarter 2023 Financial Results
4 May 23
ARS
2022 FY
Annual report to shareholders
11 Apr 23
DEF 14A
Definitive proxy
11 Apr 23
10-K
2022 FY
Annual report
23 Feb 23
8-K
Collegium Reports Fourth Quarter and Full-Year 2022 Financial Results
23 Feb 23
8-K
Collegium Pharmaceutical, Inc. Prices Upsized $210.0 Million Convertible Senior Notes Offering
13 Feb 23
8-K
Collegium Announces Fourth Quarter and Full Year 2022 Preliminary Financial Results
6 Feb 23
8-K
Regulation FD Disclosure
4 Jan 23
8-K
Appeals Court Affirms Validity of Collegium’s Belbuca® Patents
22 Dec 22
10-Q
2022 Q3
Quarterly report
3 Nov 22
8-K
Collegium Reports Third Quarter 2022 Financial Results
3 Nov 22
S-8
Registration of securities for employees
11 Aug 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
8-K
Collegium Reports Second Quarter 2022 Financial Results
4 Aug 22
8-K
Submission of Matters to a Vote of Security Holders
23 May 22
8-K/A
Financial Statements and Exhibits
13 May 22
10-Q
2022 Q1
Quarterly report
10 May 22
8-K
Collegium Reports First Quarter 2022 Financial Results
10 May 22
8-K
Regulation FD Disclosure
13 Apr 22
DEFA14A
Additional proxy soliciting materials
6 Apr 22
DEF 14A
Definitive proxy
6 Apr 22
8-K
Departure of Directors or Certain Officers
6 Apr 22
8-K
Regulation FD Disclosure
5 Apr 22
Latest ownership filings
4
Thomas B Smith
4 Mar 24
144
Notice of proposed sale of securities
29 Feb 24
4
Scott Dreyer
28 Feb 24
144
Notice of proposed sale of securities
26 Feb 24
4
Colleen Tupper
14 Feb 24
4
Scott Dreyer
14 Feb 24
4
Thomas B Smith
14 Feb 24
4
Shirley R. Kuhlmann
14 Feb 24
4
Joseph Ciaffoni
14 Feb 24
SC 13G/A
EVENTIDE ASSET MANAGEMENT, LLC
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
Rubric Capital Management LP
12 Feb 24
SC 13G/A
BlackRock Inc.
19 Jan 24
4
Scott Dreyer
18 Jan 24
144
Notice of proposed sale of securities
16 Jan 24
4
Joseph Ciaffoni
22 Dec 23
144
Notice of proposed sale of securities
21 Dec 23
4
Joseph Ciaffoni
20 Dec 23
144
Notice of proposed sale of securities
20 Dec 23
144
Notice of proposed sale of securities
19 Dec 23
144
Notice of proposed sale of securities
18 Dec 23
4
Shirley R. Kuhlmann
29 Nov 23
144
Notice of proposed sale of securities
27 Nov 23
4
Shirley R. Kuhlmann
28 Jun 23
144
Notice of proposed sale of securities
26 Jun 23
4
Joseph Ciaffoni
2 Jun 23
144
Notice of proposed sale of securities
2 Jun 23
4
Joseph Ciaffoni
1 Jun 23
144
Notice of proposed sale of securities
1 Jun 23
144
Notice of proposed sale of securities
31 May 23
144
Notice of proposed sale of securities
30 May 23
4
Rita J. Balice-Gordon
19 May 23
4
Neil F. McFarlane
19 May 23
4
Michael Thomas Heffernan
19 May 23
4
John Gordon Freund
19 May 23
4
John A. Fallon
19 May 23
4
Gwen A Melincoff
19 May 23
4
GINO SANTINI
19 May 23
4
GAREN G BOHLIN
19 May 23
4
Colleen Tupper
17 Mar 23